Literature DB >> 19397590

Arsenic trioxide suppresses paclitaxel-induced mitotic arrest.

Q Duan1, E Komissarova, W Dai.   

Abstract

OBJECTIVES: To understand if there exists a functional interaction between arsenic trioxide and paclitaxel in vitro.
MATERIALS AND METHODS: HeLa and HCT116 (rho53(+/+) and rho53(-/-)) cells were treated with As2O3 and/or paclitaxel for various times. Treated cells were collected for analyses using a combination of flow cytometry, fluorescence microscopy and Western blotting.
RESULTS: Because As(2)O(3) is capable of inhibiting tubulin polymerization and inducing mitotic arrest, we examined whether there existed any functional interaction between As(2)O(3) and paclitaxel, a well-known microtubule poison. Flow cytometry and fluorescence microscopy revealed that although As(2)O(3) alone caused a moderate level of mitotic arrest, it greatly attenuated paclitaxel-induced mitotic arrest in cells with p53 deficiency. Western blot analysis showed that As(2)O(3) significantly blocked phosphorylation of BubR1, Cdc20, and Cdc27 in cells treated with paclitaxel, suggesting that arsenic compromised the activation of the spindle checkpoint. Our further studies revealed that the attenuation of paclitaxel-induced mitotic arrest by As(2)O(3) resulted primarily from sluggish cell cycle progression at S phase but not enhanced mitotic exit.
CONCLUSION: The observations that As(2)O(3) has a negative impact on the cell cycle checkpoint activation by taxol should have significant clinical implications because the efficacy of taxol in the clinics is associated with its ability to induce mitotic arrest and subsequent mitotic catastrophe.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397590      PMCID: PMC4034259          DOI: 10.1111/j.1365-2184.2009.00606.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  35 in total

Review 1.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 2.  Cell death by mitotic catastrophe: a molecular definition.

Authors:  Maria Castedo; Jean-Luc Perfettini; Thomas Roumier; Karine Andreau; Rene Medema; Guido Kroemer
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

3.  The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells.

Authors:  Z Y Shen; J Shen; W J Cai; C Hong; M H Zheng
Journal:  Int J Mol Med       Date:  2000-02       Impact factor: 4.101

4.  Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.

Authors:  R Uslu; U A Sanli; C Sezgin; B Karabulut; E Terzioglu; S B Omay; E Goker
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide.

Authors:  P Ramírez; D A Eastmond; J P Laclette; P Ostrosky-Wegman
Journal:  Mutat Res       Date:  1997-06       Impact factor: 2.433

6.  Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions.

Authors:  B Ouyang; H Pan; L Lu; J Li; P Stambrook; B Li; W Dai
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

7.  Induction of p53 protein expression by sodium arsenite.

Authors:  A M Salazar; P Ostrosky-Wegman; D Menéndez; E Miranda; A García-Carrancá; E Rojas
Journal:  Mutat Res       Date:  1997-11-28       Impact factor: 2.433

8.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

9.  Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

Authors:  Z X Shen; G Q Chen; J H Ni; X S Li; S M Xiong; Q Y Qiu; J Zhu; W Tang; G L Sun; K Q Yang; Y Chen; L Zhou; Z W Fang; Y T Wang; J Ma; P Zhang; T D Zhang; S J Chen; Z Chen; Z Y Wang
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

10.  Toxic effects of arsenic (As3+) and other metal ions on acute promyelocytic leukemia cells.

Authors:  K Kitamura; H Yoshida; R Ohno; T Naoe
Journal:  Int J Hematol       Date:  1997-02       Impact factor: 2.490

View more
  4 in total

1.  Chromium induces chromosomal instability, which is partly due to deregulation of BubR1 and Emi1, two APC/C inhibitors.

Authors:  Liyan Hu; Xin Liu; Yana Chervona; Feikun Yang; Moon-shong Tang; Zbigniew Darzynkiewicz; Wei Dai
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

2.  Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).

Authors:  Zhiguo Li; Ying Lu; Nihal Ahmad; Klaus Strebhardt; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells.

Authors:  Clarisse S Muenyi; Abhaya P Trivedi; C William Helm; J Christopher States
Journal:  Toxicol Sci       Date:  2014-02-11       Impact factor: 4.849

Review 4.  Suppression of genomic instabilities caused by chromosome mis-segregation: a perspective from studying BubR1 and Sgo1.

Authors:  Wei Dai
Journal:  J Formos Med Assoc       Date:  2009-12       Impact factor: 3.282

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.